Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Pyrotinib|DRUG: Placebo Oral Tablet|DRUG: Trastuzumab|DRUG: Docetaxel
Sponsor: Jiangsu HengRui Medicine Co., Ltd.